Showing 1151-1160 of 1918 results for "".
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- PCA Skin Rings in the Fourth Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-rings-in-the-fourth-annual-national-peel-day/2461598/March 10, 2023 is the fourth annual National Peel Day, created by PCA SKIN. "National Peel Day was established in 2020 to drive awareness, increase education, and demystify misconceptions around the non-invasive treatment,” says Joanna Zucker, CEO CP Skin Health Group US
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Study: Psoriasis Medicine May Help Treat Alcohol Use Disorderhttps://practicaldermatology.com/news/psoriasis-medicine-may-help-treat-alcohol-use-diisorder/2461571/Apremilast may be an “incredibly promising” treatment for alcohol use disorder, according to a new study in the Journal of Clinical Investigation. On average, the people who took apremi
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Sun Pharma to Acquire Concert Pharmaceuticals, Maker of Alopecia Areata Treatment Candidatehttps://practicaldermatology.com/news/sun-pharma-to-acquire-concert-pharmaceuticals-maker-of-alopecia-areata-treatment-candidate/2461519/Sun Pharmaceutical Industries announced it has acquired Concert Pharmaceuticals for about $576 million in equity value, according to a company news release. Concert’s lead product candidate is deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of alopecia a
- University of Missouri-Columbia-Developed Teledermatology Program Improves Diagnosis of Skin Conditions in Underserved Communitieshttps://practicaldermatology.com/news/university-of-missouri-columbia-developed-teledermatology-program-improves-diagnosis-of-skin-conditions-in-underserved-communities/2461517/A teledermatology program first developed by the University of Missouri in 2015 can help improve the diagnoses of skin conditions in underserved communities, according to a new study in Journal of Telemedicine